Alkermes plc (NASDAQ:ALKS - Free Report) - Stock analysts at Zacks Research lifted their Q1 2025 earnings per share (EPS) estimates for shares of Alkermes in a research note issued to investors on Wednesday, March 5th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.29 for the quarter, up from their prior estimate of $0.22. The consensus estimate for Alkermes' current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes' Q2 2025 earnings at $0.35 EPS, Q3 2025 earnings at $0.30 EPS, Q4 2025 earnings at $0.42 EPS, FY2025 earnings at $1.35 EPS, Q1 2026 earnings at $0.25 EPS, Q2 2026 earnings at $0.34 EPS, Q3 2026 earnings at $0.24 EPS, Q4 2026 earnings at $0.36 EPS and FY2026 earnings at $1.19 EPS.
Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%.
Other equities analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a "neutral" rating and issued a $46.00 price objective on shares of Alkermes in a research note on Thursday, February 13th. Mizuho raised their price target on Alkermes from $35.00 to $40.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. Deutsche Bank Aktiengesellschaft began coverage on Alkermes in a report on Tuesday, February 11th. They issued a "buy" rating and a $40.00 price objective for the company. The Goldman Sachs Group increased their target price on Alkermes from $30.00 to $32.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Finally, UBS Group upgraded Alkermes from a "sell" rating to a "neutral" rating and boosted their target price for the stock from $21.00 to $38.00 in a research report on Tuesday, March 4th. Three analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Alkermes currently has a consensus rating of "Moderate Buy" and an average price target of $38.33.
View Our Latest Analysis on ALKS
Alkermes Trading Down 2.8 %
Shares of NASDAQ:ALKS traded down $0.98 during trading on Friday, hitting $34.26. 2,622,758 shares of the company's stock were exchanged, compared to its average volume of 1,741,370. The firm has a market cap of $5.57 billion, a P/E ratio of 15.79, a PEG ratio of 2.20 and a beta of 0.62. The firm has a 50-day moving average price of $31.98 and a two-hundred day moving average price of $29.70. Alkermes has a 1-year low of $22.90 and a 1-year high of $36.45.
Hedge Funds Weigh In On Alkermes
A number of large investors have recently bought and sold shares of ALKS. Venturi Wealth Management LLC acquired a new position in Alkermes during the fourth quarter worth $25,000. EverSource Wealth Advisors LLC lifted its position in Alkermes by 106.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company's stock worth $47,000 after buying an additional 842 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Alkermes by 2,231.5% during the 4th quarter. Blue Trust Inc. now owns 1,702 shares of the company's stock worth $49,000 after buying an additional 1,629 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Alkermes by 558.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company's stock valued at $85,000 after acquiring an additional 2,502 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in shares of Alkermes in the 4th quarter valued at about $98,000. Institutional investors and hedge funds own 95.21% of the company's stock.
Insider Buying and Selling
In related news, EVP Craig C. Hopkinson sold 100,918 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $32.05, for a total transaction of $3,234,421.90. Following the completion of the transaction, the executive vice president now directly owns 44,290 shares in the company, valued at approximately $1,419,494.50. This trade represents a 69.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.89% of the stock is currently owned by company insiders.
About Alkermes
(
Get Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Recommended Stories
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
